EU approves first of a new class of diabetes drugs

11/15/2012 | Reuters · Miami Herald (free registration), The

The European Commission approved Bristol-Myers Squibb and AstraZeneca's Forxiga, or dapagliflozin, to treat adults with type 2 diabetes. The decision makes Forxiga the first approved treatment from a new class of drugs called SGLT2 inhibitors. Forxiga, which works independently of insulin to regulate blood sugar, can be taken in combination with other type 2 diabetes drugs, or as a standalone therapy for patients who can't tolerate metformin. In January, the FDA did not approve the drug over concerns about liver and cancer risks.

View Full Article in:

Reuters · Miami Herald (free registration), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR